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Cartilage-hair hypoplasia (CHH) is a skeletal dysplasia with combined immunodeficiency,
variable clinical course and increased risk of malignancy. Management of CHH is
complicated by a paucity of long-term follow-up data, as well as knowledge on
prognostic factors. We assessed clinical course and risk factors for mortality in a
prospective cohort study of 80 patients with CHH recruited in 1985–1991 and followed
up until 2016. For all patients we collected additional health information from health
records and from the national Medical Databases and Cause-of-death Registry. The
primary outcome was immunodeficiency-related death, including death from infections,
lung disease and malignancy. Standardized mortality ratios (SMRs) were calculated using
national mortality rates as reference. Half of the patients (57%, n = 46) manifested
no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24%
(n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including
six cases of adult-onset immunodeficiency. In a significant proportion of patients (17/79,
22%), clinical features of immunodeficiency progressed over time. Of the 15 patients
with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency.
Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3–11); most commonly
from malignancy (n = 7, SMR = 10, 95%CI = 4.1–21) and lung disease (n = 4, SMR
= 46, 95%CI = 9.5–130). Mortality associated with birth length below −4 standard
deviation (compared to normal, SMR/SMR ratio = 5.4, 95%CI = 1.5–20), symptoms of
combined immunodeficiency (compared to asymptomatic, SMR/SMR ratio= 3.9, 95%CI
= 1.3–11), Hirschsprung disease (odds ratio (OR) 7.2, 95%CI = 1.04–55), pneumonia in
the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3–43/2.6–140)
and autoimmunity in adulthood (OR = 39, 95%CI = 3.5–430). In conclusion, patients
with CHH may develop adult-onset immunodeficiency or malignancy without preceding
clinical symptoms of immune defect, warranting careful follow-up. Variable disease
course and risk factors for mortality should be acknowledged.
Keywords: cancer, combined immunodeficiency, adult-onset immunodeficiency, lung disease, lymphoma,
mortality, RMRP, skeletal dysplasia
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INTRODUCTION
Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive
chondrodysplasia, with combined immunodeficiency (CID),
short stature, hair hypoplasia, anemia, increased risk of
malignancies, and Hirschsprung disease. CHH is caused by
mutations in RMRP, the gene encoding the RNA component
of mitochondrial RNA-processing endoribonuclease (1). Disease
prevalence is exceptionally high among the Amish and Finnish
populations (2). The pathogenesis involves defective cell
proliferation, impaired telomere machinery and abnormal gene
regulation (3–5). Increasedmortality in CHH relates to infections
in childhood and malignancies in young adulthood (6). Non-
Hodgkin lymphoma and basal cell carcinoma (BCC) are the
most common associated cancer types (7). In addition, lung
disease related to bronchiectasis is an important contributor to
morbidity (8).
Clinical and laboratory manifestations of CHH are highly
variable, even among siblings with the same genotype (9).
Immunodeficiency can range from asymptomatic to severe
and prediction of clinical course remains a challenge. Some
reports suggest Hirschsprung disease, short birth length or
autoimmunity to influence disease severity (9–13). Studies
exploring correlations between laboratory parameters and
clinical phenotype provide contradictory results (12, 14–16).
While early hematopoietic stem cell transplantation (HSCT)
is life-saving in severe CID, indications for HSCT in patients
with milder immunodeficiency are less clear, and prospective
studies with long-term follow-up are required to identify
prognostic factors. We have conducted a prospective clinical and
observational study in a large cohort of Finnish patients with
CHH in order to describe clinical course and long-term outcome
and to identify risk factors for early mortality.
MATERIALS AND METHODS
Study Cohort and Research Setting
All subjects and/or caregivers gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the Institutional Ethics Committee.
This prospective cohort study recruited in 1985–1991 all
Finnish patients with CHH (n = 104) based on a nation-
wide study (Figure 1) (2). Those who agreed to participate (n
= 80) were included and underwent in 1985–1991 interview,
clinical examination and blood sampling; RMRP mutations were
confirmed by Sanger sequencing when the gene was discovered
in 2001 (1).
In 2011–2015 we invited all surviving patients, 63 of the
80 patients, to follow-up visits. Those who attended (n = 32)
underwent structured interview, clinical examination and blood
sampling. For the remaining 31 patients, clinical and laboratory
data were collected from hospital records (Figure 1).
Abbreviations: BCC, basal cell carcinoma; CHH, cartilage-hair hypoplasia; CI,
confidence interval; CID, combined immunodeficiency; HSCT, hematopoietic
stem cell transplantation; SMR, standardized mortality ratio.
FIGURE 1 | Flowchart of patient recruitment and data sources used in the
study.
The cohort of 24 CHH patients who were identified in 1985–
1991 but did not agree to participate at baseline were followed for
mortality based on register data only.
Parts of the clinical and laboratory data from the baseline and
follow-up visits have been published previously in cross-sectional
study settings (9, 13, 17); in this study all available data from the
study visits were combinedwith data fromnormal clinical follow-
up visits at any health care provider and with data collected from
various registries (see below).
Register-Based Data Collection
For all 80 patients, we obtained health information from two
Finnish National Medical Databases. The Finnish National
Care Register for Health Care has since 1969 recorded
activities of health centers, hospitals, and other institutions
providing inpatient and home-nursing care in the whole country.
Outpatient primary health care data were derived from the
Finnish National Register of Primary Health Care Visits, which
covers all health centers in Finland since 2011. Database
information included health service providers, dates of visits,
diagnoses, as well as diagnostic and therapeutic procedures,
focusing on conditions associated with immunodeficiency. We
then collected all patients’ health records from all identified
hospitals for more detailed analysis. The primary outcome
was death relating to immunodeficiency, combining deaths
from infections, malignancy, and lung disease. Other recorded
and analyzed features were the development of lymphoma,
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the development of skin cancer, other malignancies besides
lymphoma and skin cancer, all types of infections, respiratory,
gastrointestinal and autoimmune diseases, anemia, diagnostic
and surgical procedures, and therapy for immunodeficiency.
Additionally, data on mortality were obtained from the
Statistics Finland, covering the period from 1971. Data from all
registries were available to the end of 2016.
Clinical Categorization
Throughout the study, we used the term “children” for
individuals aged <18 years and “adult” after 18th birthday.
We and others have previously demonstrated that laboratory
immunologic parameters are highly variable in patients
with CHH and correlate poorly with the severity of clinical
manifestations (12, 14, 17). In addition, categorization of
patients based on solely clinical symptoms has the advantage of
being easily applicable in clinical work. We therefore classified
study subjects into three groups according to clinical symptoms
of immunodeficiency without taking into account the results of
laboratory tests: (1) clinically asymptomatic immunodeficiency
(defined as no increased incidence of infections and further
referred to as “asymptomatic immunodeficiency”), (2) clinical
humoral immunodeficiency (recurrent respiratory tract
infections and/or sepsis, further referred to as “humoral
immunodeficiency”), and (3) clinical CID (additional features
of autoimmunity or opportunistic infections, further referred
to as “CID”). Opportunistic infections included thrush beyond
the first 6 months of life, Candida esophagitis, refractory warts,
recurrent mucocutaneous herpes simplex virus infections, as
well as severe varicella. Recurrent pneumonia was defined as
≥2 episodes within a year or as ≥3 episodes ever. Recurrent
otitis media and/or rhinosinusitis were defined as ≥3 episodes
within 6 months, ≥4 within a year or ≥10 ever. Refractory warts
were defined as warts persisting for years and requiring multiple
treatment courses.
This clinical immunodeficiency classification was applied (1)
at recruitment (for Kaplan–Meier analysis), (2) at 18 years (to
evaluate symptoms in childhood), (3) after 18 years (to evaluate
symptoms in adulthood) and (4) at the end of the follow-up (to
evaluate symptoms during lifetime).
Laboratory Data
Blood samples included complete blood counts (flow cytometry),
and immunoglobulin levels (nephelometry) and lymphocyte
subsets (flow cytometry), as described previously (17). We also
searched hospital records for additional results of such tests,
as well as of lymphocyte proliferation studies and vaccine
responses. We excluded children <4 years of age from the
analysis of immunoglobulin G subclasses and subjects with
ongoing immunoglobulin substitution from the analysis of
immunoglobulins, subclasses and vaccine responses.
Statistical Methods
Calculation of person-years of follow-up for each patient was
started from the date of the first research visit or 1 January
1987 (whichever was first) and ended at date of death or on 31
December 2016 (whichever was earlier). Observed numbers of
deaths and person-years were stratified by sex, 5-year age groups
and 5-year calendar periods. The expected numbers of deaths
(overall and specific causes) for each stratum were calculated
by multiplying person-years by the corresponding sex, age and
period specificmortality rates in the general population produced
by the Statistics Finland. The standardized mortality ratios
(SMRs) were calculated as an observed to expected ratio. We
stratified the causes of death into 54 categories of the longitudinal
time series of Statistics Finland (18).
Exact 95% confidence intervals (95%CI) for the SMRs were
defined with the assumption that the number of observed deaths
followed a Poisson distribution.
To test the significance of difference between SMRs in
subgroups of patients, we calculated SMR/SMR ratios and
their 95%CIs.
We then analyzed all relevant and available clinical and
laboratory features, categorized as (1) present in the first year
of life, (2) present in childhood, (3) present in adulthood and
(4) present at any age during lifetime/follow-up time, for their
association with the immunodeficiency-related mortality. The
analyses were adjusted for the patients’ sex and age at the time
of outcome.
Variables analyzed in the univariate models included
birth length and most recent height, all types of infections,
gastrointestinal, respiratory and autoimmune diseases, and
all laboratory immunologic parameters. The univariate model
analyzed each variable separately and those found to be
significant were analyzed for correlations. In the pairs of
significantly (correlation coefficient ≥0.6) correlating variables,
we excluded those with lower OR. The remaining variables
were then included in the multivariate model of the regression
analysis. The multivariate analyses were performed separately
for clinical features in childhood and in adulthood.
Statistical analyses were performed with IBM SPSS version
23 software.
RESULTS
Characteristics of the Study Cohort
The study cohort consisted of 80 patients (35 males, 45 females)
with CHH, all ethnic Finns. Median age at baseline recruitment
was 14.6 years (range from 2 weeks to 49.6 years). Median
duration of follow-up was 27.5 years (range 0.2–31.0 years) for all
subjects and 29.2 years (range 25.6–31.0 years) for the surviving
patients. All patients carried the n.71A>G RMRP variant, either
in homozygosity (n = 62, 78%) or compounded with n.263G>T
(n = 16, 20%) or a duplication at−13 (TACTCTGTGA) (n = 2,
2%) (NCBI reference sequence: NR_003051.3).
Clinical Course
Clinical and laboratory features of the study cohort were
consistent with several previous reports on Finnish patients with
CHH (8, 9, 14, 15, 17) and are therefore not further outlined or
discussed here in detail.
In a significant proportion of patients (17/79, 22%), clinical
features of immunodeficiency progressed over time (Figure 2).
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FIGURE 2 | A Sankey diagram illustrating the course of immunodeficiency (ID) from childhood to adulthood and the outcome at the end of the follow-up for 79 of the
80 patients with cartilage-hair hypoplasia; data not available for one patient.
Data on childhood symptoms were incomplete for one patient,
who was therefore excluded from the analysis of clinical course.
More than half of the patients (46/80, 57%) had asymptomatic
immunodeficiency by the end of the follow-up. Fifteen (19%) and
19 (24%) patients presented with humoral immunodeficiency
and CID, respectively.
Of the 52 subjects with asymptomatic immunodeficiency
in childhood, only 34 (65%) were alive, cancer-free and had
no symptoms of immunodeficiency at the end of follow-up.
Of the remaining 18 patients, 15 have been diagnosed with
cancer, and of them, four deceased from cancer. Another four of
these 18 patients died of immunodeficiency-unrelated causes like
accidents (n= 2), circulatory system disease (n= 1) and alcohol-
related disease (n= 1). Five of the surviving 10 patients from this
group have developed symptoms of humoral immunodeficiency.
More than half of the patients with humoral
immunodeficiency in childhood progressed to CID in adulthood.
Most patients with CID in childhood continued to suffer from
CID in adulthood associated with poor prognosis (4/7 developed
cancer and 4/7 died).
Only a few patients had been treated with prophylactic
antibiotics (n = 2), immunoglobulin replacement therapy (n =
3) or both (n = 4). Median time from the onset of recurrent
respiratory tract infections to the commencement of treatment
was 8 years for prophylactic antibiotics (range 0.5–23 years) and
16 years for immunoglobulin replacement therapy (range 5–65
years). None of the four patients with bronchiectasis in this group
had received treatment prior to the diagnosis of bronchiectasis.
None of the study patients underwent HSCT.
Malignancy
Malignancy was diagnosed in 21 out of 80 patients (31%), all
in adulthood. Of the 15 individuals with non-skin cancer, eight
had no preceding clinical symptoms of immunodeficiency. Nine
patients (11%) developed lymphoma: seven were non-Hodgkin
and five were fatal. Median age at lymphoma diagnosis was 32.5
years (range 20.2–45.4 years). In all surviving lymphoma patients,
the diagnosis was made either during a scheduled screening or
after evaluation for non-specific mild symptoms.
Skin cancer was diagnosed in 15 out of 80 patients (19%),
with 11 subjects presenting with BCC, two with squamous cell
carcinoma and another two with both. All skin cancers were
located either on the face, head, or upper limbs.
Other malignancies included single cases of lip squamous
cell carcinoma, myelodysplasia, neuroendocrine carcinoma,
plasmacytoma, thyroid carcinoma, and vocal cord carcinoma.
Altogether, five patients developed both skin and non-skin
malignancies, at variable timelines and in random order.
Mortality
Altogether, 20 of the 80 patients deceased before the end of 2016.
According to the analysis of hospital records, immunodeficiency-
related causes of death included pneumonia in children (n= 2, at
2.3 and 14.5 years), and malignancy (n = 7), respiratory disease
(n = 4) and pneumonia (n = 2) in adults (Figure 3). The four
patients who died from lung disease had been diagnosed with
lung emphysema (n = 2) and bronchiectasis (n = 4). Deaths
frommalignancy were due to lymphoma (n= 5), neuroendocrine
carcinoma (n = 1) and lip squamous cell carcinoma (n =
1). Median age at death from immunodeficiency-related causes
was 40.9 years, being 24.4 years for infections, 40.9 years for
malignancies and 52.8 years for lung disease. In addition, in
five adults, the cause of death was accidental and/or unrelated
to CHH.
Compared with the general population, patients with CHH
had significantly higher mortality rates (SMR = 7.0, 95%CI
= 4.3–11), especially due to lymphoid neoplasms (SMR = 60,
95%CI= 16–150) and diseases of the respiratory system (SMR=
46, 95%CI = 9.5–130) (Table 1). The overall SMR was similarly
increased in males (SMR = 7.1, 95%CI = 3.5–13) and females
(SMR= 7.0, 95%CI= 3.2–13).
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FIGURE 3 | Age distribution of immunodeficiency-related causes of death (n = 15) in 80 patients with cartilage-hair hypoplasia.
TABLE 1 | Mortality in a cohort of 80 patients with cartilage-hair hypoplasia in
1987–2016 (2,048 person-years)a.
Cause of death Obs Exp SMR 95%CI
All causes 20 2.85 7.0 4.3–11***
Age 0–14 2 0.09 21 2.6–77**
Age 15–29 4 0.48 8.3 2.3–21**
Age 30–44 6 0.79 7.6 2.8–17***
Age 45–74 8 1.48 65.4 2.3–11***
All diseases 17 1.93 8.8 5.1–14***
Infections 0 0.02 0.0 0.0–160
Neoplasms 7 0.69 10 4.1–21***
Malignant neoplasms 6 0.68 8.8 3.2–19***
Lymphoid/hematopoietic neoplasms 4 0.07 60 16–150***
Malignant neoplasms of lip 1 0.01 75 1.9–420*
Malignant melanoma of skin 0 0.02 0.0 0.0–230
Malignant neoplasm of breast 0 0.12 0.0 0.0–31
Other malignant neoplasms 1 0.13 7.7 0.2–43
Other neoplasms 1 0.01 98 2.5–540*
Endocrine, nutritional, and metabolic diseases 0 0.06 0.0 0.0–65
Circulatory system diseases 2 0.47 4.3 0.5–16
Respiratory system diseases 3 0.07 46 9.5–130***
Diseases of the digestive system 0 0.05 0.0 0.0–78
Congenital malformations 4 0.05 76 21–190***
Alcohol–related diseases 1 0.33 3.0 0.1–17
Accidents and violence 3 0.9 3.3 0.7–9.8
95%CI 95% confidence interval; Exp, expected number of deaths; Obs, observed number
of deaths; SMR, standardized mortality ratio.
aFor four patients the registered underlying cause of death was “congenital
malformations,” referring to CHH, which was used in the SMR analysis. However,
according to the patients’ hospital records the cause of death was pneumonia (n =
3) and lung disease (n = 1). For another patient, the registered cause of death was
“diseases of circulatory system” but hospital records indicated that patient had deceased
from pneumonia.
*p < 0.05, **p < 0.01, ***p < 0.001.
To exclude selection bias, we analyzed separately mortality
rates for the 24 Finnish patients with CHH who did not
participate the baseline study in 1985–1991. Eight of them
deceased during follow-up (8/24, 33%). Causes of death
included malignancy (n = 3), accidents (n = 2), alcohol-related
diseases (n = 1), circulatory diseases (n = 1), and congenital
malformations (n= 1).
Factors Associating With Adverse
Outcomes
Risk factors for immunodeficiency-related death included
Hirschsprung disease and pneumonia in the first year of life or
recurrently in adulthood, as well as autoimmunity in adulthood
(Tables 2, 3). In addition, all-cause mortality was significantly
higher in those with severe short stature at birth (<-4.0 standard
deviation, adjusted for gestational age) and in patients with
CID (Table 4).
We performed a Kaplan-Meier analysis (log rank test) of 80
patients, categorizing them by the degree of immunodeficiency
(asymptomatic, humoral or CID) assessed at the day of
recruitment (Figure 4). The age distribution at recruitment
was similar across these categories of immunodeficiency, as
evaluated by Kruskal–Wallis test (p = 0.159). Mean age
at recruitment was 17.3 (range 0.0–42.3), 13.3 (range 1.0–
46.0), and 22.4 (range 4.1–49.6) years for patients with
asymptomatic, humoral and combined immunodeficiency,
respectively. Survival rates for these three groups differed
significantly [χ2
(2)
= 24.8, 95%CI = 18.4–26.9, p < 0.0001],
asymptomatic children having the best and children with CID the
worst outcome.
DISCUSSION
This prospective study describes the clinical course and outcomes
of 80 Finnish patients with CHH followed for 30 years, and
demonstrates high overall mortality, mostly from malignancies
and lung disease. We also report several risk factors for mortality,
providing clinicians with useful prognostic markers.
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TABLE 2 | Risk factors for immunodeficiency-related death in a cohort of 80 patients with cartilage-hair hypoplasia.
Risk factors for
immunodeficiency-related death
OR 95%CI Spearman’s correlation coefficient Included in
multivariate analysis
Clinical features in the first year of life 0.4: A/B 0.6: B/C
A. Hirschsprung disease 15 1.8–130* 0.4: B/D, B/F, D/K +
B. Pneumonia 7.8 1.7–36** 0.3: A/F, D/J +
Clinical features in childhood 0.2: A/D, B/I, B/J
C. Pneumonia 8.2 2.3–29** 0.7: C/E 0.1: A/I, A/J, B/K, D/F, D/I −
D. Recurrent rhinosinusitis 6.8 1.1–43* 0.3: C/D 0.0: AK +
E. CID 6.7 1.2–38* −
Clinical features in adulthood
F. Autoimmune disease 42 4.2–410** 0.6: F/G, F/L, H/I +
G. CID 6.8 1.8–26** 0.4: J/K, I/J, I/K −
H. Pneumonia 5.9 1.6–22** 0.3: F/I −
I. Recurrent pneumonia 22 3.3–140** 0.1: F/J, F/K +
J. Recurrent otitis media 11 1.8–63* +
K. Recurrent rhinosinusitis 5.5 1.4–22* +
L. Low serum levels of IgG 23 2.3–230** −
All study variables were first analyzed by univariate analysis only adjusted for age and gender. Variables proven significant were then grouped by the time of onset. Significantly (correlation
coefficient >0.6, marked in bold) correlating variables were excluded and the remaining variables were combined for the multivariate analysis. 95%CI, 95% confidence interval; CID,
combined immunodeficiency; Ig, immunoglobulin; OR, odds ratio. *p < 0.05, **p < 0.01.
TABLE 3 | Risk factors for immunodeficiency-related death in a cohort of 80 patients with cartilage-hair hypoplasia, analyzed separately in childhood and adulthood.
Risk factors for immunodeficiency-
related death (n = 15)
Prevalence in patients with
outcome, N (%)
Prevalence in patients
without outcome, N (%)
OR 95%CI
Clinical features in childhooda
Hirschsprung disease 4/15 (27) 2/65 (3) 7.2 1.04–55*
Pneumonia in the first year of life 5/14 (36) 4/63 (6) 7.6 1.3–43*
Recurrent rhinosinusitis 4/14 (29) 3/61 (5) 1.6 0.1–21
Clinical features in adulthoodb
Autoimmune disease 5/13 (39) 1/65 (2) 39 3.5–430**
Recurrent pneumonia 5/13 (39) 2/65 (3) 19 2.6–140**
Recurrent otitis media 4/13 (31) 3/65 (5) 4.2 0.4–43
Recurrent rhinosinusitis 6/13 (46) 9/64 (14) 2.4 0.3–18
CI, confidence interval; Ig, immunoglobulin; N, number; OR, odds ratio. *p < 0.05, **p < 0.01.
aModel included age, gender, and on/off variables for Hirschsprung disease, pneumonia in the first year of life, and recurrent rhinosinusitis.
bModel included age, gender, and on/off variables for autoimmune disease, recurrent pneumonia, recurrent otitis media, and recurrent rhinosinusitis.
The degree of immunodeficiency in CHH is highly variable.
All previously reported Finnish patients with CHH were either
homozygous or heterozygous for the most prevalent RMRP
mutation n.71A>G, suggesting phenotype variations to be
independent of the genotype. Polymorphisms in RMRP gene and
non-allelic modifiers can explain the variable clinical features
in patients with identical RMRP variants (20, 21). Similar
phenotype-genotype inconsistency has been reported in non-
Finnish cohorts of patients with CHH, who demonstrate a much
broader spectrum of RMRPmutations (22, 23).
Large proportion of patients in our cohort remained clinically
asymptomatic for decades. However, some of them progressed
to adult-onset immunodeficiency, while others developed
fatal malignancy. This underscores the importance of careful
follow-up of also those patients who do not exhibit any
clinical symptoms of immunodeficiency. The initial humoral
immunodeficiency in childhood often evolved into CID in
adulthood and therefore should not provide a false sense of
“mild” disease. Patients with CID in childhood had the most
severe outcomes with highmortality andmight benefit from early
interventions including HSCT.
In accordance with earlier studies (7, 24), malignancy was
common in our cohort. Survival from lymphoma (4/9, 44%)
was better than previously reported (7, 24), and attributable to
early diagnosis. This highlights the value of regular screening
for lymphoma by abdominal ultrasound, which allowed for
early diagnosis in two asymptomatic patients. It also emphasizes
the need for an aggressive diagnostic approach in symptomatic
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TABLE 4 | Mortality from selected causes in 80 patients with cartilage-hair hypoplasia categorized by birth length standard deviation score and by the degree of
immunodeficiency at recruitment.
Obs Exp SMR 95%CI SMR/SMR ratio (95%CI)
CAUSES OF DEATH IN VARIOUS BIRTH LENGTH CATEGORIESa
Normal birth length (n = 28) Normal vs. moderately short
birth length: 1.8 (0.5–6.2).All deaths 6 1.47 4.1 1.5–8.9**
Neoplasms 3 0.44 6.7 1.4–20*
Lymphoid/hematopoietic neoplasms 2 0.04 53 6.4–190**
Respiratory diseases 1 0.04 24 0.6–130
Moderately short birth length (n = 39)
All deaths 8 1.11 7.2 3.1–14***
Neoplasms 3 0.20 15 3.1–44**
Lymphoid/hematopoietic neoplasms 2 0.02 87 11–320***
Respiratory diseases 0 0.02 0.0 0.0–190
Severely short birth length (n = 13) Normal vs. severely short birth
length: 5.4 (1.5–20).All deaths 6 0.27 22 8.1–48***
Neoplasms 1 0.05 20 0.5–110
Lymphoid/hematopoietic neoplasms 0 0.01 0 0.0–600
Respiratory diseases 2 0.00 430 52–1600***
CAUSES OF DEATH IN VARIOUS CATEGORIES OF IMMUNODEFICIENCY AT RECRUITMENT
Asymptomatic immunodeficiency (n = 52) Asymptomatic vs. humoral
immunodeficiency: 1.2 (0.1–5.7).All deaths 10 2.07 4.8 2.3–8.9***
Neoplasms 3 0.49 6.2 1.3–18*
Lymphoid/hematopoietic neoplasms 2 0.05 43 5.2–150**
Respiratory diseases 2 0.05 44 5.3–160**
Symptoms of humoral immunodeficiency (n = 18)
All deaths 2 0.34 5.9 0.7–21
Neoplasms 0 0.09 0 0.0–41
Lymphoid/hematopoietic neoplasms 0 0.01 0 0.0–400
Respiratory diseases 0 0.01 0 0.0–540
Symptoms of combined immunodeficiency (n = 10)
All deaths 8 0.43 19 8.0–36*** Asymptomatic vs. .combined
immunodeficiency: 3.9 (1.3-11).Neoplasms 4 0.12 34 9.3–87***
Lymphoid/hematopoietic neoplasms 2 0.01 180 22–650***
Respiratory diseases 1 0.01 79 2.0–440*
95%CI 95% confidence interval, Exp, expected number of deaths; n, number of patients; Obs, observed number of deaths; SMR, standardized mortality ratio.
aPatients birth length was adjusted for gestational age and compared with normative data for the Finnish population (19) and the standard deviation (SD) score was applied for analysis.
Patients were categorized as having normal (SD score higher than-2.0), moderately short (SD-2.0 to−4.0) or severely short (SD lower than-4.0) birth length. *p < 0.05, **p < 0.01,
***p < 0.001.
patients, illustrated by the early detection of lymphoma by
gastroscopy performed for vague abdominal pain. Lymphoma
development has been reported in CHH children as young as
six years (25), as well as in several older children (9, 26, 27). We
therefore recommend that screening for lymphoma should begin
at 5 years of age.
Many patients with no symptoms of immunodeficiency
developed malignancy during follow-up, suggesting that the
pathogenesis of lymphoma in CHH is multifactorial and that the
severity of immunodeficiency correlates poorly with the risk of
lymphoma. Lymphoproliferative disorders in patients with CHH
can be Epstein-Barr virus-driven in some (27, 28), but not all
cases (29). Therefore, not only impaired viral suppression, but
other mechanisms, such as chromosomal instability, may play a
role (30, 31). The impaired telomere biology has been reported in
patients with CHH and may contribute to the increased risk of
malignancies (4, 5).
None of the subjects in our cohort had received HSCT.
However, for several patients, HSCT has been considered,
unfortunately late in the disease course, and deemed impossible
due to poor health status. The outcome of HSCT in patients with
CHH has been reported in a series of 3, 6, 13 and 16 patients with
survival rates of 100, 100, 83, and 63%, respectively, evaluated
at 5–20 years, 1.5–22 years, 1.8–14 years and 1.6–16 years post-
transplant, respectively (16, 26, 32, 33). The majority of surviving
patients achieved full reconstitution of B and T cell numbers and
function, the quality of life was improved, and no cancer cases
have yet been reported. Early HSCT can be lifesaving in CHH,
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FIGURE 4 | Cancer-free survival in 80 patients with cartilage-hair hypoplasia differed significantly [log rank test χ2(2) = 24.8, 95%CI = 18.4–26.9, p < 0.0001]
depending on the severity of immunodeficiency at recruitment. Mean age at recruitment was 17.3 (range 0.0–42.3), 13.3 (range 1.0–46.0), and 22.4 (range 4.1–49.6)
years for patients with asymptomatic, humoral and combined immunodeficiency, respectively.
while HSCT performed after the onset of opportunistic infections
can be fatal (34). However, given the mild clinical course of some
patients with CHH and good survival after HSCT in adults with
PID (35), a more conservative approach could be possible, with
careful observation and timely detection of disease progression.
Therefore, knowledge on the risk factors for the development of
severe complications is crucial to detect subjects most likely to
benefit from HSCT.
We recognize several limitations in our study. A significant
part of health data was collected from registries and health
records from other hospitals, and we cannot ensure the
completeness of the obtained data. The number of patients with
primary outcomes and the number of events in the subgroups
of patients were small, which should be considered when
interpreting the results of multivariate analyses.
The strengths of our study include the long follow-up,
allowing for identification of risk factors for adverse outcomes.
Data were derived from several sources, including patient
interviews, causes-of death and health registries, as well as
from all available hospital records. The use of Finnish National
Health Registries allowed excellent data accuracy, coverage and
completeness (36).
In conclusion, we describe variable patterns of disease course,
highlighting the cases with adult-onset immunodeficiency or
development of malignancy in otherwise clinically asymptomatic
patients. We therefore recommend that patients with CHH who
show no clinical symptoms of immunodeficiency should also
be screened annually for malignancy including basic physical
and laboratory evaluation (at least complete blood count and
sedimentation rate) and imaging or biopsy as needed based
on symptom history. In addition, we demonstrate for the first
time that immunodeficiency-related lung disease is an important
cause of mortality in adults with CHH. Hence, patients should
undergo regular pulmonary evaluation, including diffusing
capacity of the lungs for carbon monoxide and chest imaging as
discussed previously (8). Our categorization of patients based on
clinical features of immunodeficiency predicted overall survival
and can thus be implicated in clinical practice. Most importantly,
we provide clinicians data on risk factors for mortality; these can
be used to discuss prognosis and to make management decisions.
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